Mark L. Bagarazzi

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak et al. · The Lancet · 2015 · 689 citations

Immunology, Human Papillomavirus 16, Cancer-associated Virus +17

First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response

Rob Roy MacGregor, Jean Boyer, Kenneth E. Ugen et al. · The Journal of Infectious Diseases · 1998 · 638 citations · Full text

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

Kayvon Modjarrad, Christine C. Roberts, Kristin T Mills et al. · The Lancet Infectious Diseases · 2019 · 314 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen

J J Kim, Velpandi Ayyavoo, Mark L. Bagarazzi et al. · The Journal of Immunology · 1997 · 295 citations · Full text

Immunotherapy Against HPV16/18 Generates Potent T _H 1 and Cytotoxic Cellular Immune Responses

Mark L. Bagarazzi, Jian Yan, Matthew P. Morrow et al. · Science Translational Medicine · 2012 · 279 citations · Full text